Aurora kinases as anticancer drug targets

Oliver Gautschi, Jim Heighway, Philip Mack, Phillip R. Purnell, Primo N Lara, David R Gandara

Research output: Contribution to journalArticle

325 Citations (Scopus)

Abstract

The human aurora family of serine-threonine kinases comprises three members, which act in concert with many other proteins to control chromosome assembly and segregation during mitosis. Aurora dysfunction can cause aneuploidy, mitotic arrest, and cell death. Aurora kinases are strongly expressed in a broad range of cancer types. Aurora A expression in tumors is often associated with gene amplification, genetic instability, poor histologic differentiation, and poor prognosis. Aurora Bis frequently expressed at high levels in a variety of tumors, often coincidently with aurora A, and expression level has also been associated with increased genetic instability and clinical outcome. Further, aurora kinase gene polymorphisms are associated with increased risk or early onset of cancer. The expression of aurora C in cancer is less well studied. In recent years, several small-molecule aurora kinase inhibitors have been developed that exhibit preclinical activity against a wide range of solid tumors. Preliminary clinical data from phase I trials have largely been consistent with cytostatic effects, with disease stabilization as the best response achieved in solid tumors. Objective responses have been noted in leukemia patients, although this might conceivably be due to inhibition of the Abl kinase. Current challenges include the optimization of drug administration, the identification of potential biomarkers of tumor sensitivity, and combination studies with cytotoxic drugs. Here, we summarize the most recent preclinical and clinical data and discuss new directions in the development of aurora kinase inhibitors as antineoplastic agents.

Original languageEnglish (US)
Pages (from-to)1639-1648
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number6
DOIs
StatePublished - Mar 15 2008

Fingerprint

Aurora Kinases
Pharmaceutical Preparations
Neoplasms
Chromosome Segregation
Clinical Trials, Phase I
Gene Amplification
Protein-Serine-Threonine Kinases
Cytostatic Agents
Aneuploidy
Tumor Biomarkers
Mitosis
Antineoplastic Agents
Leukemia
Cell Death
Phosphotransferases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aurora kinases as anticancer drug targets. / Gautschi, Oliver; Heighway, Jim; Mack, Philip; Purnell, Phillip R.; Lara, Primo N; Gandara, David R.

In: Clinical Cancer Research, Vol. 14, No. 6, 15.03.2008, p. 1639-1648.

Research output: Contribution to journalArticle

Gautschi, Oliver ; Heighway, Jim ; Mack, Philip ; Purnell, Phillip R. ; Lara, Primo N ; Gandara, David R. / Aurora kinases as anticancer drug targets. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 6. pp. 1639-1648.
@article{5d53e96502d441f89ad8e4121794b69e,
title = "Aurora kinases as anticancer drug targets",
abstract = "The human aurora family of serine-threonine kinases comprises three members, which act in concert with many other proteins to control chromosome assembly and segregation during mitosis. Aurora dysfunction can cause aneuploidy, mitotic arrest, and cell death. Aurora kinases are strongly expressed in a broad range of cancer types. Aurora A expression in tumors is often associated with gene amplification, genetic instability, poor histologic differentiation, and poor prognosis. Aurora Bis frequently expressed at high levels in a variety of tumors, often coincidently with aurora A, and expression level has also been associated with increased genetic instability and clinical outcome. Further, aurora kinase gene polymorphisms are associated with increased risk or early onset of cancer. The expression of aurora C in cancer is less well studied. In recent years, several small-molecule aurora kinase inhibitors have been developed that exhibit preclinical activity against a wide range of solid tumors. Preliminary clinical data from phase I trials have largely been consistent with cytostatic effects, with disease stabilization as the best response achieved in solid tumors. Objective responses have been noted in leukemia patients, although this might conceivably be due to inhibition of the Abl kinase. Current challenges include the optimization of drug administration, the identification of potential biomarkers of tumor sensitivity, and combination studies with cytotoxic drugs. Here, we summarize the most recent preclinical and clinical data and discuss new directions in the development of aurora kinase inhibitors as antineoplastic agents.",
author = "Oliver Gautschi and Jim Heighway and Philip Mack and Purnell, {Phillip R.} and Lara, {Primo N} and Gandara, {David R}",
year = "2008",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-07-2179",
language = "English (US)",
volume = "14",
pages = "1639--1648",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Aurora kinases as anticancer drug targets

AU - Gautschi, Oliver

AU - Heighway, Jim

AU - Mack, Philip

AU - Purnell, Phillip R.

AU - Lara, Primo N

AU - Gandara, David R

PY - 2008/3/15

Y1 - 2008/3/15

N2 - The human aurora family of serine-threonine kinases comprises three members, which act in concert with many other proteins to control chromosome assembly and segregation during mitosis. Aurora dysfunction can cause aneuploidy, mitotic arrest, and cell death. Aurora kinases are strongly expressed in a broad range of cancer types. Aurora A expression in tumors is often associated with gene amplification, genetic instability, poor histologic differentiation, and poor prognosis. Aurora Bis frequently expressed at high levels in a variety of tumors, often coincidently with aurora A, and expression level has also been associated with increased genetic instability and clinical outcome. Further, aurora kinase gene polymorphisms are associated with increased risk or early onset of cancer. The expression of aurora C in cancer is less well studied. In recent years, several small-molecule aurora kinase inhibitors have been developed that exhibit preclinical activity against a wide range of solid tumors. Preliminary clinical data from phase I trials have largely been consistent with cytostatic effects, with disease stabilization as the best response achieved in solid tumors. Objective responses have been noted in leukemia patients, although this might conceivably be due to inhibition of the Abl kinase. Current challenges include the optimization of drug administration, the identification of potential biomarkers of tumor sensitivity, and combination studies with cytotoxic drugs. Here, we summarize the most recent preclinical and clinical data and discuss new directions in the development of aurora kinase inhibitors as antineoplastic agents.

AB - The human aurora family of serine-threonine kinases comprises three members, which act in concert with many other proteins to control chromosome assembly and segregation during mitosis. Aurora dysfunction can cause aneuploidy, mitotic arrest, and cell death. Aurora kinases are strongly expressed in a broad range of cancer types. Aurora A expression in tumors is often associated with gene amplification, genetic instability, poor histologic differentiation, and poor prognosis. Aurora Bis frequently expressed at high levels in a variety of tumors, often coincidently with aurora A, and expression level has also been associated with increased genetic instability and clinical outcome. Further, aurora kinase gene polymorphisms are associated with increased risk or early onset of cancer. The expression of aurora C in cancer is less well studied. In recent years, several small-molecule aurora kinase inhibitors have been developed that exhibit preclinical activity against a wide range of solid tumors. Preliminary clinical data from phase I trials have largely been consistent with cytostatic effects, with disease stabilization as the best response achieved in solid tumors. Objective responses have been noted in leukemia patients, although this might conceivably be due to inhibition of the Abl kinase. Current challenges include the optimization of drug administration, the identification of potential biomarkers of tumor sensitivity, and combination studies with cytotoxic drugs. Here, we summarize the most recent preclinical and clinical data and discuss new directions in the development of aurora kinase inhibitors as antineoplastic agents.

UR - http://www.scopus.com/inward/record.url?scp=41549122837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549122837&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-2179

DO - 10.1158/1078-0432.CCR-07-2179

M3 - Article

C2 - 18347165

AN - SCOPUS:41549122837

VL - 14

SP - 1639

EP - 1648

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -